Literature DB >> 19750561

Maturation of the HIV reverse transcription complex: putting the jigsaw together.

David Warrilow1, Gilda Tachedjian, David Harrich.   

Abstract

Upon HIV attachment, fusion and entry into the host cell cytoplasm, the viral core undergoes rearrangement to become the mature reverse transcription complex (RTC). Reduced infectivity of viral deletion mutants of the core proteins, capsid and negative factor (Nef), can be complemented by vesicular stomatitis virus (VSV) pseudotyping suggesting a role for these viral proteins in a common event immediately post-entry. This event may be necessary for correct trafficking of the early complex. Enzymatic activation of the complex occurs either before or during RTC maturation, and may be dependent on the presence of deoxynucleotides in the host cell. The RTC initially becomes enlarged immediately after entry, which is followed by a decrease in its sedimentation rate consistent with core uncoating. Several HIV proteins associated with the RTC and recently identified host-cell proteins are important for reverse transcription while genome-wide siRNA knockdown studies have identified additional host cell factors that may be required for reverse transcription. Determining precisely how these proteins assist the RTC function needs to be addressed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19750561     DOI: 10.1002/rmv.627

Source DB:  PubMed          Journal:  Rev Med Virol        ISSN: 1052-9276            Impact factor:   6.989


  24 in total

Review 1.  Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription.

Authors:  Judith G Levin; Mithun Mitra; Anjali Mascarenhas; Karin Musier-Forsyth
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

2.  Detection and Tracking of Dual-Labeled HIV Particles Using Wide-Field Live Cell Imaging to Follow Viral Core Integrity.

Authors:  João I Mamede; Thomas J Hope
Journal:  Methods Mol Biol       Date:  2016

Review 3.  The high cost of fidelity.

Authors:  Sarah B Lloyd; Stephen J Kent; Wendy R Winnall
Journal:  AIDS Res Hum Retroviruses       Date:  2014-01       Impact factor: 2.205

4.  A mutant tat protein inhibits HIV-1 reverse transcription by targeting the reverse transcription complex.

Authors:  Min-Hsuan Lin; Ann Apolloni; Vincent Cutillas; Haran Sivakumaran; Sally Martin; Dongsheng Li; Ting Wei; Rui Wang; Hongping Jin; Kirsten Spann; David Harrich
Journal:  J Virol       Date:  2015-02-11       Impact factor: 5.103

5.  Zinc finger function of HIV-1 nucleocapsid protein is required for removal of 5'-terminal genomic RNA fragments: a paradigm for RNA removal reactions in HIV-1 reverse transcription.

Authors:  Christopher B Hergott; Mithun Mitra; Jianhui Guo; Tiyun Wu; Jennifer T Miller; Yasumasa Iwatani; Robert J Gorelick; Judith G Levin
Journal:  Virus Res       Date:  2012-11-10       Impact factor: 3.303

6.  Inhibition of reverse transcriptase activity increases stability of the HIV-1 core.

Authors:  Yang Yang; Thomas Fricke; Felipe Diaz-Griffero
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

7.  Eukaryotic elongation factor 1 complex subunits are critical HIV-1 reverse transcription cofactors.

Authors:  Kylie Warren; Ting Wei; Dongsheng Li; Fangyun Qin; David Warrilow; Min-Hsuan Lin; Haran Sivakumaran; Ann Apolloni; Catherine M Abbott; Alun Jones; Jenny L Anderson; David Harrich
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-24       Impact factor: 11.205

Review 8.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

Review 9.  HIV-1 uncoating: connection to nuclear entry and regulation by host proteins.

Authors:  Zandrea Ambrose; Christopher Aiken
Journal:  Virology       Date:  2014-02-20       Impact factor: 3.616

10.  Strand transfer and elongation of HIV-1 reverse transcription is facilitated by cell factors in vitro.

Authors:  David Warrilow; Kylie Warren; David Harrich
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.